JP2005519095A - 新規製剤 - Google Patents

新規製剤 Download PDF

Info

Publication number
JP2005519095A
JP2005519095A JP2003572556A JP2003572556A JP2005519095A JP 2005519095 A JP2005519095 A JP 2005519095A JP 2003572556 A JP2003572556 A JP 2003572556A JP 2003572556 A JP2003572556 A JP 2003572556A JP 2005519095 A JP2005519095 A JP 2005519095A
Authority
JP
Japan
Prior art keywords
formoterol
salts
budesonide
excipient
drug
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
JP2003572556A
Other languages
English (en)
Japanese (ja)
Other versions
JP2005519095A5 (https=
Inventor
エヴァ・トロファスト
ヤン・トロファスト
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
AstraZeneca AB
Original Assignee
AstraZeneca AB
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by AstraZeneca AB filed Critical AstraZeneca AB
Publication of JP2005519095A publication Critical patent/JP2005519095A/ja
Publication of JP2005519095A5 publication Critical patent/JP2005519095A5/ja
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0075—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a dry powder inhaler [DPI], e.g. comprising micronized drug mixed with lactose carrier particles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Pulmonology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Otolaryngology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2003572556A 2002-03-04 2003-03-03 新規製剤 Withdrawn JP2005519095A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
SE0200657A SE0200657D0 (sv) 2002-03-04 2002-03-04 Novel Formulation
PCT/SE2003/000371 WO2003074036A1 (en) 2002-03-04 2003-03-03 Novel formulation

Publications (2)

Publication Number Publication Date
JP2005519095A true JP2005519095A (ja) 2005-06-30
JP2005519095A5 JP2005519095A5 (https=) 2006-04-20

Family

ID=20287162

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2003572556A Withdrawn JP2005519095A (ja) 2002-03-04 2003-03-03 新規製剤

Country Status (6)

Country Link
US (1) US20050152847A1 (https=)
EP (1) EP1487423A1 (https=)
JP (1) JP2005519095A (https=)
AU (1) AU2003217110A1 (https=)
SE (1) SE0200657D0 (https=)
WO (1) WO2003074036A1 (https=)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5858391B2 (ja) * 2013-04-22 2016-02-10 株式会社栃木臨床病理研究所 抗腫瘍剤

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060293293A1 (en) * 2003-05-22 2006-12-28 Altana Pharma Ag Salmeterol and ciclesonide combination
US20070099883A1 (en) * 2005-10-07 2007-05-03 Cheryl Lynn Calis Anhydrous mometasone furoate formulation
US8679545B2 (en) 2005-11-12 2014-03-25 The Regents Of The University Of California Topical corticosteroids for the treatment of inflammatory diseases of the gastrointestinal tract
US8324192B2 (en) 2005-11-12 2012-12-04 The Regents Of The University Of California Viscous budesonide for the treatment of inflammatory diseases of the gastrointestinal tract
US8497258B2 (en) 2005-11-12 2013-07-30 The Regents Of The University Of California Viscous budesonide for the treatment of inflammatory diseases of the gastrointestinal tract
WO2009026434A1 (en) * 2007-08-21 2009-02-26 Alkermes, Inc. Pulmonary pharmaceutical formulations
EP2214679B1 (en) 2007-11-13 2019-03-27 Meritage Pharma, Inc. Corticosteroid compositions
US20090123551A1 (en) * 2007-11-13 2009-05-14 Meritage Pharma, Inc. Gastrointestinal delivery systems
US20090143343A1 (en) * 2007-11-13 2009-06-04 Meritage Pharma, Inc. Compositions for the treatment of inflammation of the gastrointestinal tract
US20100216754A1 (en) * 2007-11-13 2010-08-26 Meritage Pharma, Inc. Compositions for the treatment of inflammation of the gastrointestinal tract
US20090264392A1 (en) * 2008-04-21 2009-10-22 Meritage Pharma, Inc. Treating eosinophilic esophagitis

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2588005B1 (fr) * 1985-10-02 1987-12-11 Roquette Freres Maltitol poudre directement compressible et son procede de preparation
SE9302777D0 (sv) * 1993-08-27 1993-08-27 Astra Ab Process for conditioning substances
US5747445A (en) * 1993-06-24 1998-05-05 Astra Aktiebolag Therapeutic preparation for inhalation
US6290991B1 (en) * 1994-12-02 2001-09-18 Quandrant Holdings Cambridge Limited Solid dose delivery vehicle and methods of making same
SE9700136D0 (sv) * 1997-01-20 1997-01-20 Astra Ab New formulation
SE9700134D0 (sv) * 1997-01-20 1997-01-20 Astra Ab New formulation
SE9404468D0 (sv) * 1994-12-22 1994-12-22 Astra Ab Powder formulations
US5612053A (en) * 1995-04-07 1997-03-18 Edward Mendell Co., Inc. Controlled release insufflation carrier for medicaments
US5985309A (en) * 1996-05-24 1999-11-16 Massachusetts Institute Of Technology Preparation of particles for inhalation
SE9700133D0 (sv) * 1997-01-20 1997-01-20 Astra Ab New formulation
JP4691298B2 (ja) * 1999-10-12 2011-06-01 科研製薬株式会社 粉末吸入用製剤及びその製造方法

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5858391B2 (ja) * 2013-04-22 2016-02-10 株式会社栃木臨床病理研究所 抗腫瘍剤
JP2016094403A (ja) * 2013-04-22 2016-05-26 株式会社栃木臨床病理研究所 抗腫瘍剤
US9775836B2 (en) 2013-04-22 2017-10-03 Tochigi Institute Of Clinical Pathology Antitumor agent
US10149846B2 (en) 2013-04-22 2018-12-11 Tochigi Institute Of Clinical Pathology Antitumor agent
US10729683B2 (en) 2013-04-22 2020-08-04 Tochigi Institute Of Clinical Pathology Antitumor agent

Also Published As

Publication number Publication date
SE0200657D0 (sv) 2002-03-04
EP1487423A1 (en) 2004-12-22
US20050152847A1 (en) 2005-07-14
WO2003074036A1 (en) 2003-09-12
AU2003217110A1 (en) 2003-09-16

Similar Documents

Publication Publication Date Title
EP1393721B1 (en) Dosage form of powder agglomerates
ES2745439T5 (es) Partículas micronizadas de agentes activos con baja potencia de dosificación para formulaciones en polvo para inhalación
US9549936B2 (en) Method for preparing dry powder for inhalation formulation comprising salmeterol xinafoate, fluticasone propionate and tiotropium bromide
US6495167B2 (en) Preparation of powder agglomerates
US7387794B2 (en) Preparation of powder agglomerate
JP2005507881A (ja) 乾燥粉末医薬製剤
US20070071691A1 (en) Composition
JP2005519095A (ja) 新規製剤
JP2010500356A (ja) ラクトースの製造方法
KR20150010757A (ko) 신규한 투약량 및 제형
US20050244340A1 (en) Dry powder compositions
US20080292713A1 (en) Respirable Powders
KR102898819B1 (ko) 흡입용 건조 분말 제제를 위한 신규 담체 입자
RU2422144C2 (ru) Применение солей тиотропия для лечения тяжелых форм персистирующей астмы
RU2823554C1 (ru) Новые частицы носителя для сухих порошковых составов для ингаляции
HK40064779A (en) Novel carrier particles for dry powder formulations for inhalation
HK1061359B (en) Dosage form of powder agglomerates
HK1122747A (en) Dosage form of powder agglomerates

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20060228

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20060228

A761 Written withdrawal of application

Free format text: JAPANESE INTERMEDIATE CODE: A761

Effective date: 20061204